Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark
Edwards Portfolio Extended To Include Both Mitral Replacement And Repair Options
“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.
